Biomerica, Inc.
BMRA · NASDAQ
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | $5 | $5 | $5 | $19 |
| % Growth | -1.9% | 1.4% | -71.7% | – |
| Cost of Goods Sold | $5 | $5 | $5 | $16 |
| Gross Profit | $0 | $1 | $0 | $3 |
| % Margin | 9.4% | 11.3% | 8.4% | 15.8% |
| R&D Expenses | $1 | $1 | $2 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5 | $5 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $7 | $8 | $8 |
| Operating Income | -$5 | -$6 | -$7 | -$5 |
| % Margin | -96.7% | -117.6% | -135.3% | -24% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$5 | -$6 | -$7 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$6 | -$7 | -$5 |
| % Margin | -93.6% | -110.4% | -133.7% | -24% |
| EPS | -2.16 | -0.36 | -0.5 | -0.36 |
| % Growth | -500% | 28% | -38.9% | – |
| EPS Diluted | -2.16 | -0.36 | -0.5 | -0.36 |
| Weighted Avg Shares Out | 2 | 17 | 14 | 13 |
| Weighted Avg Shares Out Dil | 2 | 17 | 14 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$5 | -$6 | -$7 | -$4 |
| % Margin | -89.2% | -110.7% | -128.7% | -20.9% |